OS Therapies gears up for FDA meeting on cancer drug
NEW YORK - OS Therapies, Inc. (NYSE-A: OSTX), a small-cap biotech firm with a market capitalization of $42 million focusing on cancer treatment solutions, has announced the completion of its Phase 2b ...
OS Therapies Initiates Commercial-ready Manufacturing of OST-HER2 to Support Anticipated Biologics Licensing Authorization (BLA) Filing
OS Therapies, Inc. (NYSE-A: OSTX), a clinical-stage biotechnology company advancing immunotherapies and targeted drug conjugates for cancer treatment, today announced that it has entered into ...
verywellhealth3d
10 Tips for Living With Early-Stage HER2-Positive Breast Cancer
HER2-positive (HER2+) breast cancer treatments come with a range of unpleasant side effects. However, there are strategies ...
IFLScience3d
Plants Have Given Us Crucial Lifesaving Drugs – And Now We Risk Losing Them
These drugs, discovered decades ago, continue to save lives today, but more recent research has led to the development of ...
Nature4d
Protein design articles from across Nature Portfolio
Protein design (or protein engineering) is a technique by which proteins with enhanced or novel functional properties are created. Proteins can be engineered by rational design, which typically ...
Science Daily7d
Trastuzumab emtansine improves long-term survival in HER2 breast cancer
In patients with high-risk HER2-positive breast cancer, post-surgery, or adjuvant, treatment with trastuzumab emtansine (T-DM1) reduced the long-term risk of death or invasive disease by 46% and ...
eLife8d
Intrinsic bioenergetic adaptations compensate for reduced mitochondrial content in HER2-driven mammary tumors
However, mechanistic studies to support the conclusion that mitochondrial function is increased in the tumours remain incomplete and would benefit from experiments that would directly interrogate ...
A step towards personalized immunotherapy: MIRO device replicates tumors, environments and interactions
A team led by the Institute for Bioengineering of Catalonia (IBEC) and the Hospital del Mar Research Institute has developed ...
EurekAlert!9d
Researchers develop a device that replicates tumours to study the efficacy of immunotherapy treatments
The Micro Immune Response On chip (MIRO) allows tumours and their environment to be replicated in order to understand their response to immunotherapy-based treatments. The device, which has already ...
eLife10d
Targeting SLC7A11-mediated cysteine metabolism for the treatment of trastuzumab resistant HER2 positive breast cancer
This study presents a useful finding that targeting amino acid metabolism can overcome Trastuzumab resistance in HER2+ breast cancer. The evidence supporting the claims of the authors is solid and the ...
The American Journal of Managed Care14d
FDA Approves First HER2-Ultralow Companion Diagnostic, Expanding Treatment Eligibility
Roche’s PATHWAY HER2 (4B5) test helps identify patients with HER2-ultralow breast cancer, who may be eligible for targeted ...
The Clarion-Ledger14d
Chocolate snacks, protein powder and nutrition bars in FDA recalls. Did you buy these?
The national food safety organization also recalled several chocolate treats -- like nutrition bars, candy bars and cookies -- and protein powder in the past few weeks over undeclared milk or nut ...